CLS announces enrollment completion of initial phase of CLS-sponsored glioblastoma laser ablation study with the ClearPoint Prism™ Neuro Laser Therapy System at Skåne University Hospital
Lund, Sweden –Clinical Laserthermia Systems AB (publ) (CLS), today announced that all five patients have been safely treated in the clinical study at Skåne University Hospital (SUS).The aim of the study is to evaluate safety and feasibility of using minimally invasive MRgLITT in brain, for ablation of tumor tissue in patients diagnosed with glioblastoma. In the study, the team at Skåne University Hospital utilized CLS’s latest thermal therapy product branded ClearPoint Prism™ Neuro Laser Therapy System